[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vogt-koyanagi-harada-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vogt-koyanagi-harada-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100316407","early-immunosuppressive-therapy-on-the-course-of-vogt-koyanagi-harada-disease-100316407",false,"NCT03399175","Early Immunosuppressive Therapy on the Course of Vogt-Koyanagi-Harada Disease","Influência de imunomodulação Precoce Influence of Early Immunosuppressive Therapy on the Course of Vogt-Koyanagi-Harada Disease: a Prospective Study","Inclusion criteria:\n\n\\- acute Vogt-Koyanagi-Harada disease\n\nExclusion criteria:\n\n* non collaborative patient\n* minimum one-year follow-up","ALL","10 Years","70 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","This prospective study will include patients with Vogt-Koyanagi-Harada disease from disease onset, treated with early systemic high-dose corticosteroid and immunosuppressive therapy. Clinical and subclinical signs of disease activity added with electroretinogram exams, through predefined intervals, will be evaluated through a minimum 12-month follow-up.",[27],"Vogt Koyanagi Harada Disease",[29,30,31,32,33],"Vogt-Koyanagi-Harada disease","Immunosuppressive therapy","Indocyanine green angiography","Enhanced depth imaging optical coherence tomography","Electroretinogram","RECRUITING","2026-05-01",{"date":37,"type":38},"2026-05-07","ACTUAL",{"date":40,"type":38},"2015-03-23",{"date":42,"type":21},"2028-12",{"name":44,"class":45},"University of Sao Paulo","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":18,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":46},"100484620","a-study-of-adalimumab-in-acute-vogt-koyanagi-harada-disease-100484620","NCT05590416","A Study of Adalimumab in Acute Vogt-Koyanagi-Harada Disease","An Observational Study of Adalimumab in the Treatment of Acute Vogt-Koyanagi-Harada Disease","Inclusion Criteria:\n\n1. Subject is 18 to 70 years of age.\n2. Subjects who do not have previous, active or latent tuberculosis (TB).\n3. Subject must have Vogt-Koyanagi-Harada disease less than one month.\n4. Subject who were previously treated with systemic glucocorticoid less than one week.\n5. Subject meets at least 1 of the following criteria:\n\n1)patients who reject using systemic glucocorticoid because of the long-term side effects. 2)patients with other high-risk or systemic disease were limited by the use of glucocorticoid. 3)patients with a little reparation of retinal detachments after a week treatment with powerful systemic glucocorticoid(≥1mg\u002Fkg\u002Fday).\n\nExclusion Criteria:\n\n1. Subject with confirmed or suspected infectious uveitis, including but not limited to infectious uveitis due to TB, cytomegalovirus (CMV), Human T-Lymphotropic Virus Type 1 (HTLV-1), Whipple's disease, Herpes Zoster virus (HZV), Lyme disease, toxoplasmosis and herpes simplex virus (HSV).\n2. Subject with corneal or lens opacity that precludes visualization of the fundus or that likely requires cataract surgery during the duration of the trial.\n3. Subject has previous exposure to anti-tumor necrosis factor (TNF) therapy or any biologic therapy with a potential therapeutic impact on non-infectious uveitis.\n4. Subject has received Ozurdex® (dexamethasone implant) within 6 months prior to the Baseline visit.\n5. Subject has received intravitreal anti-VEGF therapy within 45 days of the Baseline visit for Lucentis® (ranibizumab) or Avastin® (bevacizumab) or within 60 days of the Baseline visit for anti-VEGF Trap (aflibercept).\n6. Subject has received intravitreal methotrexate within 90 days prior to the Baseline visit.","18 Years",{"count":56,"type":21},15,"OBSERVATIONAL","This project is designed to test the hypothesis that adalimumab is clinically useful for patients with acuta Vogt-Koyanagi-Harada disease",[60,61],"Vogt-Koyanagi-Harada Disease","Adalimumab","2024-07-01",{"date":64,"type":38},"2024-07-03",{"date":66,"type":38},"2021-06-01",{"date":68,"type":21},"2024-12-30",{"name":70,"class":45},"Tianjin Medical University"]